Transient low-affinity agonist binding to Torpedo postsynaptic membranes resolved by using sequential mixing stopped-flow fluorescence spectroscopy.
We have detected the binding of the fluorescent agonist Dns-C6-Cho to both low- and high-affinity states of the nicotinic acetylcholine receptor (nAcChoR) using sequential mixing stopped-flow fluorescence spectroscopy. Our approach to resolving low- and high-affinity binding was to first preincubate receptor membranes with the fluorescent partial agonist Dns-C6-Cho for 15 ms to 1000 s and then to follow the fluorescence decay upon chemical dilution into excess acetylcholine. The fast and slow decays, reflecting Dns-C6-Cho dissociation from low- and high-affinity receptors, had rates of 140 +/- 27 s-1 and 0.1 +/- 0.02 s-1, respectively. With increasing preincubation times, the number of low-affinity receptors decreased while the number of high-affinity receptors increased in a Dns-C6-Cho concentration-dependent manner consistent with current models for agonist-induced affinity state conversion. At receptor-activating concentrations of Dns-C6-Cho, the apparent rates with which high-affinity receptors formed approximated those of ion flux desensitization, implying that the fast desensitized state has an agonist dissociation rate that is indistinguishable from the equilibrium slow desensitized state. The KD for the low-affinity binding site was determined to be 1.1 microM from the increase in the amplitude of the fast decay with Dns-C6-Cho concentration with preincubation times that were sufficiently brief to minimize affinity state conversion. Assuming a bimolecular association rate of 10(8) M-1 s-1, a second estimate of 1.4 microM was made for low-affinity binding. We also detected a fluorescence enhancement consistent with a conformational isomerization of Dns-C6-Cho-inhibited nAcChoRs.
Raines
D E
DE
Department of Anesthesia and Critical Care, Massachusetts General Hospital, Boston 02114, USA.
Krishnan
N S
NS
D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D003619:Dansyl Compounds / Q000378:metabolism* / Q000494:pharmacology*; D005456:Fluorescent Dyes / Q000378:metabolism*; D007473:Ion Channels / Q000037:antagonists & inhibitors; D008956:Models, Chemical; D000442:Octanols / Q000494:pharmacology; D011487:Protein Conformation; D000644:Quaternary Ammonium Compounds / Q000378:metabolism* / Q000494:pharmacology*; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000378:metabolism; D013050:Spectrometry, Fluorescence / Q000379:methods; D013570:Synaptic Membranes / Q000187:drug effects / Q000378:metabolism*; D014101:Torpedo
D003619:Dansyl Compounds; D005456:Fluorescent Dyes; D007473:Ion Channels; D000442:Octanols; D000644:Quaternary Ammonium Compounds; D011950:Receptors, Cholinergic; C027933:(1-(5-dimethylaminonaphthalene)sulfonamido)-n-hexanoic acid-beta-N-trimethylammonium ethyl ester